{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:10:36Z","timestamp":1772500236484,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0094050","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T20:59:17Z","timestamp":1397163557000},"page":"e94050","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Systematic Comparison of the Anti-Tumoural Activity and Toxicity of the Three Adv-TKs"],"prefix":"10.1371","volume":"9","author":[{"given":"Qinglei","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wencheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danni","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"key":"ref1","first-page":"6070","article-title":"Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints","volume":"62","author":"T Reid","year":"2002","journal-title":"Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/mthe.2002.0658","article-title":"Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes","volume":"6","author":"H Ben-Gary","year":"2002","journal-title":"Mol Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/10430340152712638","article-title":"Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions","volume":"13","author":"BG Harvey","year":"2002","journal-title":"Hum Gene Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","article-title":"Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma","volume":"9","author":"N Habib","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1006\/mthe.2001.0444","article-title":"Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial","volume":"4","author":"MW Sung","year":"2001","journal-title":"Mol Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.gt.3301512","article-title":"Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial","volume":"8","author":"T Reid","year":"2001","journal-title":"Gene Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/10430340150218369","article-title":"E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors","volume":"12","author":"NA Habib","year":"2001","journal-title":"Hum Gene Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1128\/JVI.73.8.6729-6742.1999","article-title":"Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs","volume":"73","author":"BG Harvey","year":"1999","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.1997.8.8-985","article-title":"Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine","volume":"8","author":"RG Crystal","year":"1997","journal-title":"Hum Gene Ther"},{"key":"ref10","first-page":"693","article-title":"Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies","volume":"9","author":"D Makower","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref11","first-page":"3989","article-title":"Bystander effect in herpes simplex virus-thymidine kinase\/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication","volume":"60","author":"M Mesnil","year":"2000","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00268-002-4053-5","article-title":"Current progress in suicide gene therapy for cancer","volume":"26","author":"K Yazawa","year":"2002","journal-title":"World J Surg"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-07-0499","article-title":"Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma","volume":"13","author":"N Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/sj.onc.1204094","article-title":"Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer","volume":"19","author":"D Kirn","year":"2000","journal-title":"Oncogene"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.1158\/1078-0432.CCR-05-1085","article-title":"Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability","volume":"11","author":"J Zhou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/carcin\/bgp249","article-title":"A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity","volume":"30","author":"Z Han","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ymthe.2005.12.009","article-title":"Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus","volume":"13","author":"Q Gao","year":"2006","journal-title":"Mol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1535-7163.MCT-07-2134","article-title":"Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration","volume":"7","author":"X Huang","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.cgt.7700967","article-title":"Oncolytic adenovirus-mediated transfer of the anti-sense Chk2 selectively inhibits tumor growth in vitro and in vivo","volume":"13","author":"G Chen","year":"2006","journal-title":"Cancer Gene Therapy"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-07-0499","article-title":"Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma","volume":"13(19)","author":"N Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0952-7915(99)80064-8","article-title":"Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic","volume":"11","author":"WS Wold","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1074\/jbc.M008218200","article-title":"Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2","volume":"276","author":"CA Benedict","year":"2001","journal-title":"J Biol Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.gt.3301507","article-title":"Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7K\/gp19K region","volume":"8","author":"LK Hawkins","year":"2001","journal-title":"Gene Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1128\/JVI.66.6.3633-3642.1992","article-title":"The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection","volume":"66","author":"AE Tollefson","year":"1992","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/viro.1996.0295","article-title":"The E3\u201311.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants","volume":"220","author":"AE Tollefson","year":"1996","journal-title":"Virology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/JVI.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3\u201311.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"AE Tollefson","year":"1996","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1128\/JVI.77.14.7764-7778.2003","article-title":"Mutations within the ADP (E3\u201311.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells","volume":"77","author":"AE Tollefson","year":"2003","journal-title":"J Virol"},{"key":"ref28","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"TL DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"ref29","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"I Ganly","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.gt.3302436","article-title":"Phase I\u2013II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas","volume":"12","author":"E Galanis","year":"2005","journal-title":"Gene Ther"},{"key":"ref31","unstructured":"Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, <etal>et al<\/etal>.. (2007) Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 196: 389 e381\u2013389; discussion 389 e389\u2013310."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfn168","article-title":"Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates","volume":"106","author":"C Su","year":"2008","journal-title":"Toxicol Sci"},{"key":"ref33","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"SO Freytag","year":"2003","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Y Wang","year":"2003","journal-title":"Nat Biotechnol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/cgt.2009.5","article-title":"An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector","volume":"16(8)","author":"DL Lichtenstein","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"ref36","first-page":"19","article-title":"Isolation, growth, and purification of defective adenovirus deletion mutants","volume":"130","author":"G Ketner","year":"2007","journal-title":"Methods Mol Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood.V90.7.2738","article-title":"Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model","volume":"90","author":"D Ma","year":"1997","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-61779-080-5_15","article-title":"Isolation and culture of ovarian cancer cells and cell lines","volume":"731","author":"CM Kurbacher","year":"2011","journal-title":"Methods Mol Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbrc.2005.07.039","article-title":"Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor","volume":"335","author":"P Wu","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/aps.2009.33","article-title":"Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase\/ganciclovir in hepatic carcinoma animal models","volume":"30","author":"FQ Zheng","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/mt.2008.162","article-title":"Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model","volume":"16","author":"MA Thomas","year":"2008","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0153540","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0094050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T16:06:56Z","timestamp":1597680416000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0094050"}},"subtitle":[],"editor":[{"given":"Marta M.","family":"Alonso","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0094050","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0153540","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}